logo
Twitter
Discord
Email
logo
ZimVie Inc.

ZimVie Inc.

NASDAQ•ZIMV
CEO: Mr. Vafa Jamali
Sector: Healthcare
Industry: Medical - Devices
Listing Date: 2022-02-16
ZimVie Inc., together with its subsidiaries, develops, manufactures, and markets a portfolio of products and solutions designed to support dental tooth replacement and restoration procedures worldwide. It operates through The Dental Segment. The company offers dental implant systems; biomaterials; prosthetic and abutment products, surgical instrumentation, and kits; and patient-specific restorative solutions, such as abutments, bars, implant bridges, and hybrid restorations under the BellaTek brand name. It provides bone grafts, barrier membranes, and collagen wound care products; virtual treatment planning services, guided surgery solutions, CAD/CAM workflow systems, and intra-oral scanners; and Implant Concierge, a web-based treatment planning and surgery guide service. The company sells its products to oral surgeons, dental specialists, general dentists, dental laboratories, and other dental organizations, including DSOs, as well as educational, medical, and governmental entities, hospitals, and surgery centers through direct sales representatives, agents, and distributors. ZimVie Inc. was incorporated in 2021 and is headquartered in Palm Beach Gardens, Florida with additional facilities around the globe.
Contact Information
4555 Riverside Drive, Palm Beach Gardens, FL, 33410, United States
303-443-7500
www.zimvie.com
Market Cap
$535.63M
P/E (TTM)
-27.3
33.5
Dividend Yield
--
52W High
$19.01
52W Low
$8.15
52W Range
100%
Rank66Top 89.6%
1.9
F-Score
Modified Piotroski Analysis
Based on 7-year fundamentals
Weak • 1.9 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2018-2024

Financial Dashboard

Q2 2025 Data

Revenue

$116.66M-0.13%
4-Quarter Trend

EPS

-$0.14-6.67%
4-Quarter Trend

FCF

$1.65M-6.97%
4-Quarter Trend

2025 Q2 Earnings Highlights

Key Highlights

Operating Profit Swing Swung to operating profit of $2.1M for six months versus prior year loss of $(9.5)M, driven by efficiencies.
Continuing Operations Loss Narrows Net loss from continuing operations improved to $(6.5)M for six months, significantly better than $(21.1)M last year.
Merger Announced $19.00 Cash Entered agreement for acquisition at $19.00 per share cash, representing a 99% premium over recent trading price.
SG&A Expenses Decline Selling, general, and administrative expenses fell to $118.6M for six months, down from $122.7M previous period.

Risk Factors

Merger Execution Uncertainty Consummation subject to stockholder approval and regulatory clearance; failure risks termination fees up to $20.3M.
Trade Policy Volatility New U.S. tariffs and retaliatory actions create uncertainty impacting procurement costs and potential sales volume globally.
Litigation Challenges Merger Lawsuits may seek injunctions, potentially preventing or delaying the expected timeframe for the proposed acquisition closing.
Foreign Currency Exposure Exposed to EUR and JPY fluctuations impacting net sales; managed via foreign currency exchange forward contracts.

Outlook

Post-Merger Private Company Upon closing, ZimVie will become a privately held company; future costs related to the merger cannot be estimated now.
Restructuring Completion Expected Restructuring plan initiated post-spine sale expected to complete by end of 2025; minimal further charges anticipated.
Liquidity Position Adequate Believe available cash and credit facility sufficient to meet liquidity needs, including capital expenditures, for next 12 months.
New Tax Law Evaluation Currently evaluating effects of recently enacted One Big Beautiful Bill Act on consolidated financial statements and ETR.

Peer Comparison

Revenue (TTM)

Varex Imaging CorporationVREX
$844.60M
+4.1%
Orthofix Medical Inc.OFIX
$818.06M
+4.3%
Avanos Medical, Inc.AVNS
$699.90M
+2.7%

Gross Margin (Latest Quarter)

SI-BONE, Inc.SIBN
79.8%
+0.8pp
OrthoPediatrics Corp.KIDS
73.9%
+0.5pp
Orthofix Medical Inc.OFIX
72.2%
+3.5pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
BFLY$812.10M-10.1-37.8%6.3%
SIBN$798.79M-33.1-14.2%16.0%
PACB$641.55M-1.3-289.5%87.2%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
4.2%
Moderate Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
75%
Volatile Cash Flow

Research & Insights

Reports
All Years

  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Jul 30, 2025|
    Revenue: $116.66M-0.1%
    |
    EPS: $-0.14-6.7%
    Miss

  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: May 8, 2025|
    Revenue: $112.00M-5.2%
    |
    EPS: $-0.05-82.8%
    Miss

  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Feb 26, 2025|
    Revenue: $449.75M-1.7%
    |
    EPS: $-0.94+93.7%
    Miss

  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Oct 30, 2024|
    Revenue: $103.22M-49.1%
    |
    EPS: $-0.08-57.9%
    Miss

  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Aug 1, 2024|
    Revenue: $116.81M-48.1%
    |
    EPS: $-0.15-83.1%
    Miss

  • Form 10-Q - Q1 2024

    Period End: Mar 31, 2024|Filed: May 8, 2024|
    Revenue: $118.20M-47.6%
    |
    EPS: $-0.29-74.6%
    Miss

  • Form 10-K - FY 2023

    Period End: Dec 31, 2023|Filed: Feb 28, 2024|
    Revenue: $457.43M-49.9%
    |
    EPS: $-14.87-506.9%
    Miss

  • Form 10-Q - Q3 2023

    Period End: Sep 30, 2023|Filed: Nov 1, 2023|
    Revenue: $202.87M-5.5%
    |
    EPS: $-0.19-695.6%
    Miss